{"category": "ham", "to_address": "ip-health@lists.essential.org", "from_address": "Joana Ramos <jdr@ramoslink.info>", "subject": "[Ip-health] Novartis buys exclusive rights to anti-smoking `vaccine`", "body": " http://www.zeenews.com/znnew/articles.asp?aid=367864&ssid=53&sid=BUS\n\nNovartis buys exclusive rights to anti-smoking `vaccine`\n\n\nBasel (Switzerland), April 26: Novartis AG said today it will pay Cytos\nBiotechnology AG up to 600 million Swiss francs (USD 500 million) for\nthe exclusive right to develop, produce and market an experimental drug\nit hopes will help cure smokers of their habit.\n\nThe pharmaceuticals giant said it would initially pay Cytos 35 million\nfrancs (USD 29 million), with further payments dependent on the success\nof the new drug, NicQb, which is being billed as an anti-smoking\n\"vaccine.\" NicQb, which is still in clinical trials, blocks the nicotine\nrush people experience when smoking a cigarette.\n\nNovartis said the drug had the potential to help an estimated 1 billion\nsmokers worldwide who want to quit. Shares in Cytos, a spin-off from the\nSwiss Federal Institute of Technology, jumped 6 per cent on the news to\nreach 1.75 francs (USD 1.45) on the Zurich exchange. Novartis shares\nwere down 0.2 per cent at 69.90 francs (USD 58.11).\n\n--\nJoana Ramos, MSW\nCancer Resources & Advocacy\nSeattle WA USA\nTel. +1-206-229-2420\nhttp://ramoslink.info/\nwww.cancersurvivorsproject.org\nwww.healthyskepticism.org\n\n\n\n\n_______________________________________________\nIp-health mailing list\nIp-health@lists.essential.org\nhttp://lists.essential.org/mailman/listinfo/ip-health\n\n"}